Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais Sells 68,684 Shares of Stock

Xencor, Inc. (NASDAQ:XNCR) VP John R. Desjarlais sold 68,684 shares of Xencor stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the transaction, the vice president now owns 200,104 shares of the company’s stock, valued at $4,698,441.92. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Xencor Price Performance

Shares of Xencor stock opened at $23.61 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 1 year low of $15.31 and a 1 year high of $26.84. The company’s fifty day moving average is $20.84 and its two-hundred day moving average is $20.37.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.98) by $0.27. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. During the same quarter in the previous year, the firm posted ($0.40) EPS. The firm’s revenue for the quarter was down 81.9% on a year-over-year basis. As a group, sell-side analysts forecast that Xencor, Inc. will post -3.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Wedbush reaffirmed an “outperform” rating and set a $38.00 price objective on shares of Xencor in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price objective on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, Royal Bank of Canada increased their price target on shares of Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $35.75.

Hedge Funds Weigh In On Xencor

Several institutional investors have recently bought and sold shares of XNCR. Darwin Global Management Ltd. acquired a new stake in shares of Xencor in the 1st quarter worth $24,557,000. Logos Global Management LP lifted its position in Xencor by 130.8% in the second quarter. Logos Global Management LP now owns 1,500,000 shares of the biopharmaceutical company’s stock valued at $28,395,000 after purchasing an additional 850,000 shares during the period. Point72 Asset Management L.P. boosted its holdings in Xencor by 52.9% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,261,789 shares of the biopharmaceutical company’s stock valued at $23,886,000 after purchasing an additional 436,389 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Xencor by 9.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,819,656 shares of the biopharmaceutical company’s stock valued at $84,530,000 after purchasing an additional 335,881 shares in the last quarter. Finally, Baker BROS. Advisors LP increased its position in Xencor by 122.2% during the 1st quarter. Baker BROS. Advisors LP now owns 545,431 shares of the biopharmaceutical company’s stock worth $12,070,000 after purchasing an additional 300,000 shares during the period.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.